CORT
Corcept Therapeutics Incorporated · Healthcare · Medical - Pharmaceuticals
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +10 | 52.52M | $4.57B | +17 | −8 |
| Q1 2026 | 107 | -4 | 51.80M | $2.09B | +8 | −13 |
| Q4 2025 | 112 | 0 | 56.18M | $1.96B | +1 | — |
| Q3 2025 | 18 | -2 | 41.55M | $3.45B | +1 | −4 |
| Q2 2025 | 18 | +1 | 38.50M | $2.83B | +1 | — |
| Q1 2025 | 14 | +1 | 15.71M | $1.80B | +1 | — |
| Q4 2024 | 13 | 0 | 16.40M | $826.20M | — | — |
| Q3 2024 | 12 | -1 | 13.66M | $632.44M | — | −1 |
| Q2 2024 | 13 | — | 13.78M | $447.82M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 6.91M | — | $224.59M | 0.4% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.28M | — | $74.07M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Arrowstreet Capital ✦ | 1.48M | — | $48.20M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 949.14K | — | $30.84M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 822.12K | — | $26.71M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 393.78K | — | $12.79M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 302.30K | — | $9.82M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 259.65K | — | $8.44M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | AQR Capital Management ✦ | 239.06K | — | $7.77M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | T. Rowe Price ✦ | 51.13K | — | $1.66M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 45.26K | — | $1.47M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 12 | Gotham Asset Management ✦ | 24.95K | — | $810,788 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 20.20K | — | $656,298 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 347 holders, 79.01M shares, $2.83B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.45K sh · $514,389
Officer · 8.74K sh · $1.02M
Officer · 15.84K sh · $1.84M
Officer · 5.15K sh · $600,063
Officer · 2.09K sh · $241,412
Officer · 1.10K sh · $125,973
Officer · 4.74K sh · $552,869
Officer · 810 sh · $93,473
Officer · 413 sh · $47,717
Officer · 296 sh · $29,843
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology